MediWound (NASDAQ:MDWD - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.23, RTT News reports. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. During the same period last year, the firm earned ($0.19) EPS.
MediWound Stock Down 4.6 %
Shares of NASDAQ MDWD traded down $0.78 during mid-day trading on Friday, reaching $16.27. 239,922 shares of the company were exchanged, compared to its average volume of 90,154. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00. The stock has a market capitalization of $175.60 million, a PE ratio of -5.61 and a beta of 0.82. The company's 50 day moving average price is $18.17 and its 200 day moving average price is $17.59.
Analyst Upgrades and Downgrades
MDWD has been the subject of several analyst reports. StockNews.com raised shares of MediWound to a "sell" rating in a report on Friday. Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of MediWound in a report on Thursday.
Get Our Latest Analysis on MediWound
MediWound Company Profile
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Read More
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
